Harbour Investments Inc. Has $686,000 Stock Holdings in AstraZeneca PLC (NASDAQ:AZN)

Harbour Investments Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 1.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,805 shares of the company’s stock after purchasing an additional 160 shares during the quarter. Harbour Investments Inc.’s holdings in AstraZeneca were worth $686,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently made changes to their positions in AZN. Martin Investment Management LLC lifted its stake in AstraZeneca by 2.8% in the 3rd quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock valued at $22,571,000 after purchasing an additional 7,615 shares during the last quarter. Integrated Advisors Network LLC lifted its position in shares of AstraZeneca by 46.6% in the third quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after buying an additional 13,860 shares during the last quarter. Creative Planning lifted its position in shares of AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after buying an additional 16,692 shares during the last quarter. Northcape Wealth Management LLC bought a new position in shares of AstraZeneca during the 2nd quarter worth approximately $269,000. Finally, Cetera Advisors LLC increased its holdings in shares of AstraZeneca by 124.5% during the 1st quarter. Cetera Advisors LLC now owns 98,262 shares of the company’s stock worth $6,657,000 after acquiring an additional 54,488 shares during the last quarter. Institutional investors own 20.35% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the company. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. TD Cowen raised their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. Finally, Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Two analysts have rated the stock with a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $89.75.

AstraZeneca Trading Down 2.8 %

Shares of AstraZeneca stock opened at $63.23 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.69 and a current ratio of 0.93. The firm has a 50-day moving average of $75.03 and a 200-day moving average of $78.20. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The stock has a market cap of $196.05 billion, a PE ratio of 30.25, a PEG ratio of 1.21 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a net margin of 12.68% and a return on equity of 30.01%. The firm had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. During the same quarter in the previous year, the firm posted $0.87 EPS. The business’s revenue for the quarter was up 18.0% compared to the same quarter last year. As a group, sell-side analysts forecast that AstraZeneca PLC will post 4.07 EPS for the current year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.